Evan Seigerman
Stock Analyst at BMO Capital
(3.85)
# 690
Out of 4,915 analysts
145
Total ratings
54.64%
Success rate
8.3%
Average return
Main Sectors:
Stocks Rated by Evan Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INCY Incyte | Maintains: Underperform | $52 → $60 | $76.26 | -21.32% | 13 | Jul 30, 2025 | |
| IRON Disc Medicine | Maintains: Outperform | $112 → $120 | $60.41 | +98.66% | 6 | May 12, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $96 → $115 | $131.88 | -12.80% | 15 | May 6, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $115 → $120 | $115.25 | +4.12% | 17 | Apr 17, 2025 | |
| BIIB Biogen | Maintains: Market Perform | $156 → $139 | $128.73 | +7.98% | 27 | Feb 13, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $520 → $545 | $466.86 | +16.74% | 15 | Jan 31, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Market Perform | $57 → $61 | $43.83 | +39.17% | 11 | Nov 12, 2024 | |
| LLY Eli Lilly and Company | Maintains: Outperform | $1,001 → $1,101 | $764.49 | +44.02% | 8 | Aug 9, 2024 | |
| GPCR Structure Therapeutics | Initiates: Outperform | $40 | $17.83 | +124.34% | 1 | Feb 28, 2023 | |
| REPL Replimune Group | Maintains: Outperform | $30 → $40 | $7.15 | +459.44% | 1 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $757 → $788 | $554.36 | +42.15% | 17 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $8 → $2.5 | $2.43 | +2.88% | 2 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $263 → $243 | $300.50 | -19.13% | 6 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $6.62 | +81.27% | 2 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $23.74 | +152.74% | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $30 | $1.61 | +1,763.35% | 3 | May 12, 2020 |
Incyte
Jul 30, 2025
Maintains: Underperform
Price Target: $52 → $60
Current: $76.26
Upside: -21.32%
Disc Medicine
May 12, 2025
Maintains: Outperform
Price Target: $112 → $120
Current: $60.41
Upside: +98.66%
Neurocrine Biosciences
May 6, 2025
Maintains: Market Perform
Price Target: $96 → $115
Current: $131.88
Upside: -12.80%
Gilead Sciences
Apr 17, 2025
Maintains: Outperform
Price Target: $115 → $120
Current: $115.25
Upside: +4.12%
Biogen
Feb 13, 2025
Maintains: Market Perform
Price Target: $156 → $139
Current: $128.73
Upside: +7.98%
Vertex Pharmaceuticals
Jan 31, 2025
Maintains: Outperform
Price Target: $520 → $545
Current: $466.86
Upside: +16.74%
Bristol-Myers Squibb Company
Nov 12, 2024
Maintains: Market Perform
Price Target: $57 → $61
Current: $43.83
Upside: +39.17%
Eli Lilly and Company
Aug 9, 2024
Maintains: Outperform
Price Target: $1,001 → $1,101
Current: $764.49
Upside: +44.02%
Structure Therapeutics
Feb 28, 2023
Initiates: Outperform
Price Target: $40
Current: $17.83
Upside: +124.34%
Replimune Group
Oct 14, 2022
Maintains: Outperform
Price Target: $30 → $40
Current: $7.15
Upside: +459.44%
Aug 4, 2022
Maintains: Outperform
Price Target: $757 → $788
Current: $554.36
Upside: +42.15%
Aug 2, 2022
Downgrades: Market Perform
Price Target: $8 → $2.5
Current: $2.43
Upside: +2.88%
Apr 28, 2022
Maintains: Market Perform
Price Target: $263 → $243
Current: $300.50
Upside: -19.13%
Mar 31, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $6.62
Upside: +81.27%
Nov 19, 2021
Initiates: Outperform
Price Target: $60
Current: $23.74
Upside: +152.74%
May 12, 2020
Maintains: Outperform
Price Target: $13 → $30
Current: $1.61
Upside: +1,763.35%